Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXJB4N)

• Drug Name: BMS-536924 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 135440466
  ChEBI ID: CHEBI:91454
  CAS Number: CAS 468740-43-4
  TTD Drug ID: DMXJB4N

Molecule-Related Drug Atlas

Drug(s) Targeting G1/S-specific cyclin-E1 (CCNE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PD-0183812	DMWYP86	Retinoblastoma	2D02.2	Terminated	[4]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[5]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[6]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[6]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[6]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[6]
aloisine A	DM5U1LN	Discovery agent	N.A.	Investigative	[7]
3-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol	DMJZK40	Discovery agent	N.A.	Investigative	[5]
(2'Z,3'E)-5-Chloro-5'-chloro-indirubin-3'-oxime	DMGXRSZ	Discovery agent	N.A.	Investigative	[8]
(2'Z,3'E)-5-Chloro-5'-methyl-indirubin-3'-oxime	DMZ0V6G	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting LCK tyrosine protein kinase (LCK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dasatinib	DMJV2EK	Chronic myelogenous leukaemia	2A20.0	Approved	[9]
VX-680	DM93YKJ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
JNJ-26483327	DMSQ3AZ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
ISIS-CRP	DMQDUG4	Cardiovascular disease	BA00-BE2Z	Phase 1	[11]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[12]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[12]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[13]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[12]
AMP-PNP	DMTOK1D	Discovery agent	N.A.	Investigative	[14]
KN-62	DMLZ89P	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Focal adhesion kinase 1 (FAK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VS-6063	DMGBLI3	Mesothelioma	2C51.2	Phase 2	[15]
BI-853520	DMNOSYW	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
PF-562271	DMSLE03	Solid tumour/cancer	2A00-2F9Z	Phase 1	[17]
VS-4718	DMN9JCD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
GSK-2256098	DMR24MI	Pulmonary arterial hypertension	BB01.0	Phase 1	[19]
CEP-37440	DMV632P	Solid tumour/cancer	2A00-2F9Z	Phase 1	[16]
IN10018	DMPXOVA	Metastatic melanoma	2E2Z	Phase 1	[20]
1,2,4-triazolo[1,5a]pyridine derivative 1	DMIUPSA	N. A.	N. A.	Patented	[21]
PF-228	DM32FKD	Discovery agent	N.A.	Investigative	[22]
PMID23414845C30	DMNVQ29	Discovery agent	N.A.	Investigative	[23]

Drug(s) Targeting Albendazole monooxygenase (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[24]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[25]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[14]
ML-3163	DM3S5UC	Discovery agent	N.A.	Investigative	[26]
6-(3-Hydroxy-phenyl)-naphthalen-2-ol	DMH8WA2	Discovery agent	N.A.	Investigative	[27]
2-(2-(4-tert-Butylphenylthio)ethyl)-1H-imidazole	DMZVBPG	Discovery agent	N.A.	Investigative	[28]
ML-3375	DMXJY6W	Discovery agent	N.A.	Investigative	[26]
ML-3403	DMTQWI8	Discovery agent	N.A.	Investigative	[26]
4-[5-(3-Hydroxyphenyl)-3-thienyl]-2-methylphenol	DM7ERYJ	Discovery agent	N.A.	Investigative	[29]
2-Fluoro-4-[5-(3-hydroxyphenyl)-2-thienyl]phenol	DMUGAT8	Discovery agent	N.A.	Investigative	[29]

Drug(s) Targeting Proto-oncogene c-Met (MET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[30]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[31]
Capmatinib	DMYCXKL	Non-small-cell lung cancer	2C25.Y	Approved	[32]
Tepotinib	DMUQ0E8	Non-small cell lung cancer	2C25	Approved	[33]
Amivantamab	DMZ7AMY	Non-small-cell lung cancer	2C25.Y	Phase 3	[34]
RG3638	DMTQJE0	Gastric adenocarcinoma	2B72	Phase 3	[35]
Savolitinib	DMALFKX	Renal cell carcinoma	2C90	Phase 3	[36]
Beperminogene perplasmid	DM6RWBN	Critical limb ischemia	BD4Y	Phase 3	[37]
Tivantinib	DMNVP8Q	Hepatocellular carcinoma	2C12.02	Phase 3	[38]
MGCD516	DM752PU	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[35]

Drug(s) Targeting Insulin-like growth factor I receptor (IGF1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Teprotumumab	DM4L59B	Graves disease	5A02.0	Approved	[39]
Mecasermin	DM1O3BY	Growth failure	LD2F.1Y	Approved	[40]
Somatomedin-1	DMZ9FAO	Hormone deficiency	5A61.1	Approved	[41]
OSI-906	DMHKZLF	Solid tumour/cancer	2A00-2F9Z	Phase 3	[42]
Rinfabate	DML9FD4	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[43]
MM-141	DM2RJ4D	Pancreatic cancer	2C10	Phase 2	[44]
TT-100	DMZE6Y9	Non-small-cell lung cancer	2C25.Y	Phase 2	[45]
AMG 479	DM0DRAZ	Breast cancer	2C60-2C65	Phase 2	[46]
VPI-2690B	DMUQZT4	Diabetic nephropathy	GB61.Z	Phase 2	[47]
AXL-1717	DMTQ1Y3	Solid tumour/cancer	2A00-2F9Z	Phase 2	[48]

Drug(s) Targeting Platelet-derived growth factor receptor alpha (PDGFRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[49]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[50]
Olaratumab	DMNYOIX	Soft tissue sarcoma	2B57	Approved	[51]
Avapritinib	DMK2GZX	Gastrointestinal stromal tumour	2B5B	Approved	[52]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[53]
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[54]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[55]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[56]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[57]
MEDI-575	DMI9WVM	Glioblastoma multiforme	2A00.0	Phase 2	[58]

Drug(s) Targeting Extracellular signal-regulated kinase 2 (ERK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BVD-523	DMNB4XK	Melanoma	2C30	Phase 2	[59]
HH2710	DM0C5MV	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[60]
ASTX029	DMVZXIA	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[61]
VAN-10-4-eluting stent	DM3ZW6A	Artery stenosis	BD52	Phase 1	[62]
GDC-0994	DMFC2OY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[63]
JSI-1187	DMVJWBS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[64]
LY3214996	DMFDAY7	Solid tumour/cancer	2A00-2F9Z	Phase 1	[36]
CHIR-99021	DMB8MNU	Allergic inflammation	4A80-4A85	Patented	[65]
COR-D	DMLXMCB	T-cell leukaemia	2A90	Preclinical	[66]
SB220025	DMSBUET	Arthritis	FA20	Terminated	[67]

Drug(s) Targeting Platelet-derived growth factor receptor beta (PDGFRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[68]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[49]
Becaplermin	DM1R5X4	Diabetic complication	5A2Y	Approved	[69]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[53]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[55]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[56]
MK-2461	DM21WBH	Alzheimer disease	8A20	Phase 1/2	[70]
SNN-0031	DM2X3BR	Brain injury	NA07.Z	Phase 1/2	[71]
TAK-593	DMNFZOT	Solid tumour/cancer	2A00-2F9Z	Phase 1	[72]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[73]

Drug(s) Targeting RAC-alpha serine/threonine-protein kinase (AKT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[36]
AZD5363	DM9SKW8	Triple negative breast cancer	2C60-2C65	Phase 3	[36]
GDC-0068	DMWBZJD	Breast cancer	2C60-2C65	Phase 3	[36]
CI-1033	DMSI8N3	Lymphoma	2A80-2A86	Phase 2	[9]
CMX-2043	DMPSCVY	Cardiac disease	BA00-BE2Z	Phase 2	[74]
ARQ 092	DM5WK0J	Proteus syndrome	LD2C	Phase 2	[75]
GSK2110183	DMZHB37	leukaemia	2A60-2B33	Phase 2	[76]
RX-0201	DMTBAV3	Pancreatic cancer	2C10	Phase 2	[77]
Trametinib + 2141795	DMYP7TO	Solid tumour/cancer	2A00-2F9Z	Phase 2	[76]
PTX-200	DM0ZIT2	Breast cancer	2C60-2C65	Phase 2	[36]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[78]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[79]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[80]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[81]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[82]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[78]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[83]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[84]
CYC065	DM9ODT6	Lymphoma	2A80-2A86	Phase 1	[36]

Drug(s) Targeting Vascular endothelial growth factor receptor 2 (KDR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[68]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[85]
Regorafenib	DMHSY1I	Metastatic colorectal cancer	2B91	Approved	[30]
Sunitinib	DMCBJSR	Gastrointestinal cancer	2C11	Approved	[86]
Axitinib	DMGVH6N	Renal cell carcinoma	2C90	Approved	[87]
Vandetanib	DMRICNP	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
Pazopanib HCl	DM6U9CQ	Renal cell carcinoma	2C90	Approved	[88]
Cabozantinib	DMIYDT4	Thyroid cancer	2D10	Approved	[31]
Tivozanib	DMUKC5L	Renal cell carcinoma	2C90	Approved	[89]
Lenvatinib	DMB1IU4	Thyroid cancer	2D10	Approved	[90]

Drug(s) Targeting ERBB2 messenger RNA (HER2 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HKI-272	DM6QOVN	Breast cancer	2C60-2C65	Phase 3	[91]
BMS-690514	DMX302C	Chronic pain	MG30	Phase 2	[92]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[6]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[6]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[6]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[6]
PMID24915291C38	DMBXT9J	Discovery agent	N.A.	Investigative	[93]
Geldanamycin-estradiol hybrid	DMUSJ96	Discovery agent	N.A.	Investigative	[94]
CL-387785	DMLKFZC	Discovery agent	N.A.	Investigative	[95]
HDS-029	DMLRUVA	Discovery agent	N.A.	Investigative	[95]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Albendazole monooxygenase (CYP3A4)	TTXV4FI	CP3A4_HUMAN	Inhibitor	[2]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
ERBB2 messenger RNA (HER2 mRNA)	TTR5TV4	ERBB2_HUMAN	Inhibitor	[1]
Extracellular signal-regulated kinase 2 (ERK2)	TT4TQBX	MK01_HUMAN	Inhibitor	[1]
Focal adhesion kinase 1 (FAK)	TTON5IT	FAK1_HUMAN	Inhibitor	[1]
G1/S-specific cyclin-E1 (CCNE1)	TTCEJ4F	CCNE1_HUMAN	Inhibitor	[1]
Insulin-like growth factor I receptor (IGF1R)	TTHRID2	IGF1R_HUMAN	Inhibitor	[3]
LCK tyrosine protein kinase (LCK)	TT860QF	LCK_HUMAN	Inhibitor	[1]
Platelet-derived growth factor receptor alpha (PDGFRA)	TT8FYO9	PGFRA_HUMAN	Inhibitor	[1]
Platelet-derived growth factor receptor beta (PDGFRB)	TTI7421	PGFRB_HUMAN	Inhibitor	[1]
Proto-oncogene c-Met (MET)	TTNDSF4	MET_HUMAN	Inhibitor	[1]
RAC-alpha serine/threonine-protein kinase (AKT1)	TTWTSCV	AKT1_HUMAN	Inhibitor	[1]
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Inhibitor	[1]

References

• [1] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [2] Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)py... J Med Chem. 2008 Oct 9;51(19):5897-900.
• [3] SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1744-8.
• [4] Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases. J Med Chem. 2000 Nov 30;43(24):4606-16.
• [5] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [6] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [7] Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J Med Chem. 2003 Jan 16;46(2):222-36.
• [8] 5,5'-substituted indirubin-3'-oxime derivatives as potent cyclin-dependent kinase inhibitors with anticancer activity. J Med Chem. 2010 May 13;53(9):3696-706.
• [9] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [10] National Cancer Institute Drug Dictionary (drug id 596693).
• [11] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [12] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [13] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [14] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [15] Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
• [16] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [17] Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther. 2011 Nov;10(11):2135-45.
• [18] FAK Inhibition disrupts a beta5 integrin signaling axis controlling anchorage-independent ovarian carcinoma growth. Mol Cancer Ther. 2014 Aug;13(8):2050-61.
• [19] A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells. Cell Cycle. 2014;13(19):3143-9.
• [20] Clinical pipeline report, company report or official report of InxMed.
• [21] Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143.
• [22] Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
• [23] Structure-based discovery of cellular-active allosteric inhibitors of FAK. Bioorg Med Chem Lett. 2013 Mar 15;23(6):1779-85.
• [24] Structure-activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. Eur J Med Chem. 2008 Aug;43(8):1621-31.
• [25] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [26] Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. J Med Chem. 2003 Jul 17;46(15):3230-44.
• [27] Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors... J Med Chem. 2008 Apr 10;51(7):2158-69.
• [28] Role of hydrophobic substituents on the terminal nitrogen of histamine in receptor binding and agonist activity: development of an orally active hi... J Med Chem. 2010 May 13;53(9):3840-4.
• [29] New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxyst... J Med Chem. 2009 Nov 12;52(21):6724-43.
• [30] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [31] Clinical pipeline report, company report or official report of Exelixis (2011).
• [32] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [33] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [34] Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209.
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1815).
• [36] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [37] Beperminogene perplasmid for the treatment of critical limb ischemia. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1145-56.
• [38] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7948).
• [39] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [40] IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.
• [41] 2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
• [42] Imidazo[2,1-b]thiazoles: multitargeted inhibitors of both the insulin-like growth factor receptor and members of the epidermal growth factor family... Bioorg Med Chem Lett. 2010 Apr 15;20(8):2452-5.
• [43] Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3. Drugs R D. 2005;6(2):120-7.
• [44] MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther. 2014 Feb;13(2):410-25.
• [45] BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
• [46] Clinical pipeline report, company report or official report of Amgen (2009).
• [47] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [48] Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011 Apr;50(3):441-7.
• [49] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [50] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [51] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
• [52] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [53] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [54] The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
• [55] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [56] National Cancer Institute Drug Dictionary (drug id 452042).
• [57] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [58] Clinical pipeline report, company report or official report of MedImmune (2011).
• [59] DOI: 10.1158/1538-7445.AM2015-4693
• [60] Clinical pipeline report, company report or official report of HaiHe Biopharma.
• [61] Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
• [62] WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
• [63] ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
• [64] National Cancer Institute Drug Dictionary (drug name JSI1187).
• [65] Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
• [66] Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
• [67] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [68] Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
• [69] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [70] MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010 Feb 15;70(4):1524-33.
• [71] Company report (Neuronova)
• [72] Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. Biochemistry. 2011 Feb 8;50(5):738-51.
• [73] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [74] Pre-clinical and Clinical Safety Studies of CMX-2043: a cytoprotective lipoic acid analogue for ischaemia-reperfusion injury. Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):456-64.
• [75] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [76] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1479).
• [77] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [78] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [79] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [80] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [81] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [82] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [83] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [84] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [85] Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. J Med Chem. 2002 Dec 19;45(26):5687-93.
• [86] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [87] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [88] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [89] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
• [90] Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
• [91] Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41.
• [92] Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.
• [93] Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.
• [94] Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett. 1999 May 3;9(9):1233-8.
• [95] Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.